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Germline MUTYH gene mutations are not
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Abstract
MUTYH-associated polyposis (MAP) is an autosomal recessive disease, which predisposes to polyposis and colorectal
cancer. There is a trend towards an increased risk of breast cancer in MAP patients, with a remarkable proportion of
papillary breast cancers. To determine whether MUTYH mutations are associated with this specific and rare type of
breast cancer, 53 unselected patients with papillary breast cancer were analyzed for founder mutations in the
MUTYH gene. No germline mutations were identified, indicating that biallelic MUTYH mutations are not a frequent
underlying cause for the development of papillary carcinomas of the breast.
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Introduction
MUTYH-associated polyposis (MAP) is an autosomal re-
cessive disease, which was first identified by El-Tassan
et al. in 2002 [1]. Several studies confirmed the association
between germline MUTYH mutations and colorectal ad-
enomas and colorectal carcinomas [2-4]. The MUTYH
gene is involved in base excision repair (BER) preventing
G:C→ T:A conversions. These conversions are caused by
oxidative damage forming 8-oxo-7,8-dihydro-2-deoxygua-
nosine (8-oxoG) resulting in a mis-incorporation of ade-
nine that, if not repaired by MUTYH DNA glycosylase,
could lead to a G:C→ T:A conversion [5-7]. In the Dutch
population the mutations p.Y179C, p.G396D and p.P405L
account for approximately 90% of all MUTYH germline
mutations [8,9].
Several studies on extracolonic cancers in MAP patients
have been performed. In one study in MAP patients in
which the histological subtype of the breast tumors were
included, two out of eleven breast cancers were described
as intracystic papillary type [10]. Also, the occurrence of
MUTYH mutations in patients with breast cancer has
been examined. Some of these studies found a significant
increase in MUTYH mutations in breast cancer patients,
while others could not find this potential association.
[11-15]. Two of these studies specified the breast cancer
histological subtypes of the patients. Out et al. found that
minor allele genotypes of several MUTYH variants
showed a trend towards association with lobular BC hist-
ology [14], while Rennert et al. found no differences for
ductal or other BC histology type among 30 patients het-
erozygous for p.Gly396Asp or p.Tyr179Cys and 359 pa-
tients homozygous wild-type for these mutations [15].
Intracystic papillary breast cancer accounts for less than
1% of the total amount of breast cancer [16,17], however,
this type has been observed in an unexpectedly high pro-
portion of MAP patients. We therefore wondered whether
papillary carcinomas of the breast could be used as a hall-
mark to recognize patients with MAP. To explore whether
biallelic MUTYH mutations are a frequent cause under-
lying the development of papillary carcinomas of the
breast, we analyzed the prevalence of germline MUTYH
mutations in an unselected patient group with papillary
breast cancer.
* Correspondence: nicoline.hoogerbrugge@radboudumc.nl
†Equal contributors
1Department of Human Genetics, Radboud university medical center, P.O.
Box 9101, 6500 HB, Nijmegen, The Netherlands
Full list of author information is available at the end of the article
© 2014 Boesaard et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Boesaard et al. Hereditary Cancer in Clinical Practice 2014, 12:21
http://www.hccpjournal.com/content/12/1/21
Methods
Patient samples
The study group consisted of 74 patients with papillary
carcinomas of the breast, including papillary ductal car-
cinoma in situ (DCIS), intraductal/intracystic papillary
carcinomas and invasive papillary carcinomas, which
were diagnosed between January 1990 and December
2012 in the Radboud university medical center, and be-
tween January 2002 and December 2012 in the Canisius
Wilhelmina Hospital, Nijmegen. Cases were retrieved
from the surgical pathology files. Information concern-
ing other malignancies or polyposis coli was obtained
from pathology records using the PALGA (nationwide
histopathology and cytopathology data archive of the
Netherlands) database. All records were anonymously
listed in a database. Cases were treated according to the
FEDERA (Dutch Federation of Biomedical Societies)
code, with anonymous use of redundant tissue for re-
search purposes.
DNA analysis
DNA was isolated from formalin-fixed paraffin-embedded
(FFPE) tissue. Preferably normal (“benign”) tissue was
selected. If no benign tissue was available, which was
the case for two patients, tissue containing tumor ma-
terial was used. FFPE tissue was reviewed to exclude
presence of tumor cells before and after DNA isolation
with H&E-stained slides. DNA concentration of the
samples was measured using the Nanodrop ND-1000
(Thermo Fisher Scientific, USA) and Qubit 1.0 (Life
Technologies Corporation, UK). The quality of samples
was evaluated by performing a DNA size ladder poly-
merase chain reaction (PCR). Patients for whom the
isolated DNA was of insufficient quality were excluded
from the study. MUTYH primers were developed using
the UCSC Browser (Table 1) and the DNA was ampli-
fied using PCR. The PCR product was enzymatically
purified, after which sequencing was performed using
Big-Dye terminator sequencing (BigDye Terminators v
1.1 (Applied Biosystems, USA)). The sequence data was
analyzed using Vector NTI advance V11.0 (Invitrogen
corporations, USA) and Chromas Lite (Technelysium,
Australia). The following three founder mutations were
evaluated; c.536A>G (p.Y179C), c.1187G>A (p.G396D)
and c.1214C>T (p.P405L).MUTYH mutations were anno-
tated according to the most recent version of the reference
sequence, NM_001128425.1.
Results
Tissue was available from 72 of in total 74 patients with
papillary breast cancer; benign tissue was available from
70 patients and for two patients we used malignant tis-
sue. Patient characteristics are depicted in Table 2. Six
patients (8.3%) had a DCIS of the papillary type, 49 pa-
tients (68.1%) had an intraductal or intracystic papillary
carcinoma with no signs of invasion in the surrounding
tissue and in 17 patients (23.6%) an invasive component
was found which originated from the intraductal or
intracystic papillary carcinoma or papillary type DCIS.
Within our total cohort of breast cancer patients, 9 pa-
tients were also diagnosed with at least 1 adenoma of
the colon and 4 patients with a metachronous or syn-
chronous colon carcinoma were present.
From 53 patients (73.6%), including 9 patients with a
colorectal adenoma and 3 patients with a colon carcin-
oma, the quality of the isolated DNA was sufficient for
further use in analysis of the three most common
founder mutations in the Dutch population. The aver-
age age was 67 years (SD 13 years) with a range of 22
to 96 years, which is comparable with a population
wide study on patients with a papillary carcinoma of
the breast [18]. No MUTYH mutations were found
(Table 3).
Table 1 Primers used for amplification
Variant Forward primer (5' - 3') Reverse primer (5' - 3') Product
p.Y179C CCCCCTAGCTCCTCTACCAC CGGGTGATCTCTTTGACCTC 202 bp
p.G396D and p.P405L AGCCCAACGCTGTAGTTCCT GAGGGCAGTGGCATGAGTAA 182 bp
Bp = Base pair.
Table 2 Patient characteristics
Patients, n Sequenced (N = 53) All patients (N = 72)
Sex (Male/Female) 52 female, 1 male 71 female, 1 male
Age at diagnosis
(range)
67.5 years (range
22–89 years)
67.4 years (range
22–96 years)
Histological type
– Papillary DCIS 3 (5.7%) 6 (8.3%)
– Intraductal/
intracystic PC
39 (73.6%) 49 (68.1%)
– PC with invasive
component
11 (20.8%) 17 (23.6%)
Patients with colon
adenomas
9 (17.0%) 9 (12.5%)
Patients with colon
carcinoma
3 (5.7%) 4 (5.6%)
PC = Papillary carcinoma; DCIS = Ductal carcinoma in situ.
Table 3 Mutation analysis
Patients, n p.Y179C p.G396D p.P405L
N = 53 0/53 0/53 0/53
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Discussion
Our data do not confirm that biallelic germline MUTYH
mutations are a frequent underlying cause of papillary
carcinomas of the breast. Such relation was previously
suggested by the results of Vogt et al. that showed an
overrepresentation of intraductal papillary carcinomas of
the breast in a MAP cohort [10]. Papillary carcinomas of
the breast are a group of tumors with a favorable prog-
nosis [19]. The terminology of papillary carcinomas has
been widely disputed. The intraductal and intracystic
papillary carcinomas were first considered as a form of
carcinoma in situ, but it was shown that they often com-
pletely lack a myoepithelial layer and can be invasive
[20]. Some authors prefer to use the term encapsulated
papillary carcinoma, which refers to intracystic and solid
papillary tumors, which are circumscribed and mostly
have a fibrous capsule [21]. For this article, we have
made a differentiation between papillary DCIS, intraduc-
tal or intracystic papillary carcinomas and papillary car-
cinomas with an invasive component. As the definition
of the various histological variants of this malignant
tumor differs in the literature, we decided to include in
our study all the previously described papillary tumors.
In our study, papillomas of the breast were excluded be-
cause a relation between this benign tumor and malig-
nant papillary carcinomas has not been described.
In our study we could not identify the association be-
tweenMUTYH mutations and papillary carcinomas of the
breast in an unselected group of patients with papillary
carcinomas. The current approach has been used in other
studies in cancer predisposition syndromes. For example,
patients with Familial Adenomatous Polyposis, caused by
mutations in the APC gene, have a higher risk of develop-
ing desmoid tumors, but when a unselected cohort of this
rare type of tumor is tested for APC mutations, only a
small mutation detection rate has been found [22,23]. The
same accounts for patients with endometrial cancer that are
screened for Lynch syndrome-predisposing genes [24,25].
Based on the data presented in this study, an enrich-
ment of biallelic MUTYH mutations in other patient
cohorts cannot be excluded. This might be true for
patients with other histological subtypes of BC, patients
with very early onset of papillary carcinoma, patients with
papillary carcinomas of the breast together with polyposis
as well as patients with a family history of colon carcinomas.
Our data, however, do indicate that papillary carcinomas of
the breast cannot be used as a hallmark to recognize
patients withMUTYH-associated polyposis.
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